BridgeBio Pharma's (BBIO) Overweight Rating Reaffirmed at Cantor Fitzgerald

BridgeBio Pharma (NASDAQ:BBIO – Get Free Report)‘s stock had its “overweight” rating restated by research analysts at Cantor Fitzgerald in a report released on Tuesday, Benzinga reports. They presently have a $70.00 price objective on the stock. Cantor Fitzgerald’s price objective would indicate a potential upside of 152.34% from the stock’s current price. BBIO has […]

Related Keywords

Texas , United States , Arizona , Bridgebio Pharma , Bio Pharma , Randalw Scott , Cantor Fitzgerald , Citigroup , Kokusai Asset Management Co , Securities Exchange Commission , Mitsubishi Ufj , Bridgebio Pharma Inc , Moody Aldrich Partners , Jpmorgan Chase Co , Bridgebio Pharma Company Profile , Get Free Report , Director Randal , Exchange Commission , Retirement System , Asset Management , State Retirement System , Aldrich Partners , Amalgamated Bank , Bridgebio Pharma Daily ,